PRA announced the recent creation of a legal entity in Bulgaria to support continued growth and expand operations in the Balkan area. Located in Sofia, the new entity will enhance PRA’s local presence, provide a solid base for growth, and strengthen PRA’s ability to provide professional quality clinical services in Bulgaria and neighboring countries.
PRA began operating in Romania and Greece in 2006, and demand for services in the Balkan region has steadily increased and expanded to Turkey and Bulgaria. PRA's staff has grown accordingly and the number of feasibilities and awarded projects nearly tripled in the past year alone.
“In addition to our presence in the Central and Eastern European region, PRA’s new entity in Bulgaria is a part of our strategic growth and development that clearly demonstrates our commitment to expansion,” said Dr. Ludger Langer, PRA’s Vice President of Clinical Operations in Europe, Asia-Pacific and Africa.
The legal entity in Bulgaria further demonstrates our commitment to meeting the expanding needs of our clients in an ever-changing clinical trials environment and provides our local teams with a local corporate basis for operations.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.